Conference Coverage

VIDEO: Expert outlines new thinking on irritable bowel syndrome


 

AT ACG 2015

HONOLULU – New medications and more patient-focused strategies are changing the treatment of irritable bowel syndrome, as physicians move away from simply treating symptoms and gain a better understanding of IBS processes and mechanisms of action.

“I think there’s kind of an explosion in medications for functional bowel disease, specifically irritable bowel syndrome, over the last couple years, because we’ve gotten a lot smarter about how we think about these patients and how we treat these patients,” explained Dr. Darren M. Brenner, director of the functional bowel program at Northwestern University, Chicago.

In an interview at the annual meeting of the American College of Gastroenterology, Dr. Brenner discussed new approaches to target the syndrome’s mechanisms of action, new thinking by the Food and Drug Administration on IBS drug approval, and the wide range of traditional, complementary and alternative, and diet-related therapeutic options now available to patients.

Recommended Reading

Evidence builds for aspirin’s benefit in GI cancers
MDedge Family Medicine
Study linked three genetic risk variants to alcohol-related cirrhosis
MDedge Family Medicine
IDWeek: Despite better drugs, HCV deaths keep rising
MDedge Family Medicine
IDWeek: VA found no evidence of CRE transmission through duodenoscopes
MDedge Family Medicine
GI bleeds in obese patients more complicated but no more fatal
MDedge Family Medicine
Risk score assesses likelihood of fecal transplant failure
MDedge Family Medicine
Disparity found in PPI risk perception among physicians
MDedge Family Medicine
New targeted Crohn’s therapy performs well in phase III trial
MDedge Family Medicine
VIDEO: Gut microbiota may predict C. diff treatment response
MDedge Family Medicine
VIDEO: Serum amyloid A could be IBD biomarker
MDedge Family Medicine